This product is a dibenzodiazepine antipsychotic. It has a strong blocking effect on the 5-hydroxytryptamine (5-HT2A) receptor and dopamine (DA1) receptor in the brain, and also has a blocking effect on the dopamine (DA4) receptor, and a weaker blocking effect on the dopamine (DA2) receptor. In addition, it also has anticholinergic (M1), antihistamine (H1) and anti-α-adrenaline receptor effects. Extrapyramidal reactions are rare, and generally do not cause an increase in blood prolactin. It can directly inhibit the ascending activation system of the brainstem reticular formation and has a strong sedative and hypnotic effect.

Phenothiazine antipsychotics block dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways, and have blocking effects on dopamine (DA1) receptors, 5-hydroxytryptamine receptors, M-type acetylcholine receptors, and α-adrenaline receptors; at low doses, they can inhibit dopamine receptors in the medulla oblongata emetic chemoreceptor area, and at high doses, they can directly inhibit the vomiting center to produce a powerful antiemetic effect; they can inhibit the body temperature regulation center to lower body temperature, block peripheral α-adrenaline receptors to cause vasodilation, leading to a drop in blood pressure, and have a certain effect on the endocrine system.

No specific pharmacological effects are clearly mentioned from the above information

This product belongs to the benzamide antipsychotic drug. Its characteristic action is to selectively block the dopamine (DA2) receptors of the mesolimbic system, with little effect on other neurotransmitter receptors, mild anticholinergic effect, and no obvious sedative and anti-excitement and agitation effects. This product also has strong antiemetic and gastric juice secretion inhibitory effects.

This product is the earliest sulfonamide antibiotic used for intestinal infections.